Lyka Labs Limited Stock

Equities

LYKALABS

INE933A01014

Pharmaceuticals

Market Closed - NSE India S.E. 07:40:30 2024-04-24 am EDT 5-day change 1st Jan Change
128.2 INR -0.47% Intraday chart for Lyka Labs Limited -0.47% +3.60%
Sales 2022 1.84B 22.15M Sales 2023 894M 10.74M Capitalization 2.99B 35.95M
Net income 2022 390M 4.68M Net income 2023 -132M -1.59M EV / Sales 2022 2.72 x
Net Debt 2022 1.12B 13.5M Net Debt 2023 632M 7.58M EV / Sales 2023 4.05 x
P/E ratio 2022
9.99 x
P/E ratio 2023
-22.5 x
Employees 296
Yield 2022 *
-
Yield 2023
-
Free-Float 37.33%
More Fundamentals * Assessed data
Dynamic Chart
Lyka Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Lyka Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Lyka Labs Gets Indian Regulator's Nod to Market Tofacitinib Ointment MT
Lyka Labs Limited Receives Product Permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w CI
Lyka Labs Limited Announces Cessation of Sandeep Parikh as Independent Director CI
Lyka Labs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Lyka Labs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Lyka Labs Limited announced that it has received INR 453.375 million in funding from Ipca Laboratories Limited CI
Lyka Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Lyka Labs Limited announced that it expects to receive INR 453.375 million in funding from Ipca Laboratories Limited CI
Lyka Labs Limited completed the acquisition of Animal Healthcare Business from Agilis Healthcare Pvt. Ltd. for INR 32.5 million. CI
Lyka Labs to Acquire Agilis' Animal Healthcare Business MT
Lyka Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Lyka Labs Limited agreed to acquire Animal Healthcare Business from Agilis Healthcare Pvt. Ltd. for INR 35 million. CI
More news
1 day-0.47%
1 week-0.47%
Current month+20.83%
1 month+18.54%
3 months+7.01%
6 months+17.61%
Current year+3.60%
More quotes
1 week
125.00
Extreme 125
134.40
1 month
104.90
Extreme 104.9
134.40
Current year
104.90
Extreme 104.9
144.30
1 year
88.50
Extreme 88.5
144.30
3 years
34.05
Extreme 34.05
267.00
5 years
9.60
Extreme 9.6
267.00
10 years
9.60
Extreme 9.6
267.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 37 10-03-31
Director of Finance/CFO 63 14-06-30
Compliance Officer - 22-11-08
Members of the board TitleAgeSince
Director/Board Member 76 22-08-07
Chairman 73 23-08-07
Director of Finance/CFO 63 14-06-30
More insiders
Date Price Change Volume
24-04-24 128.2 -0.47% 54 913
24-04-23 128.8 +0.66% 80,215
24-04-22 128 -0.70% 109,823
24-04-19 128.8 +0.04% 90,964
24-04-18 128.8 +2.43% 473,308

Delayed Quote NSE India S.E., April 24, 2024 at 07:40 am EDT

More quotes
Lyka Labs Limited is an India-based company that is engaged in the business of pharmaceutical and related activities, including research. The Company is focused on lyophilization - formulations/bulk sterile active pharmaceutical ingredients (APIs), and new product development including novel drug delivery systems in both topical preparation and lyophilized products. The Company manufactures pharmaceutical products, such as dry powder, liquid injections, lyophilized injections, ointment/creams and lotions, and external preparations for several international markets and the domestic market. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, anti-fungal, anti-malarial, anti-bacterial, corticosteroid hormones and cephalosporins. The Company's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
More about the company
  1. Stock Market
  2. Equities
  3. LYKALABS Stock